FDA Approves COVID Vaccine Mix & Match Approach
Following a decision by the US Food and Drug Administration to allow individuals to receive a different booster shot than the first COVID-19 vaccination, the Russian Direct Investment Fund (RDIF, Russian Sovereign Wealth Fund) has announced the Russian Sputnik V vaccine. Is one of the best solutions to pandemics. The mix-and-match approach pioneered by Sputnik V enhances and prolongs the immune response, increases the effectiveness of vaccines against new mutations, and provides flexibility in vaccination efforts around the world.
The FDA’s decision to approve the mixing and matching of COVID booster shots in the United States is yet another confirmation of the effectiveness of Sputnik V’s core vaccine cocktail approach.
Sputnik V as a Global Pioneer of Heterologous Vaccination
Sputnik V combines human adenovirus serotype 26 as the first component and human adenovirus serotype 5 as the second component. Heterogeneous boost approaches have proven successful against coronaviruses. Sputnik V confirmed an overall effectiveness of 91.4%, which provides the creation of strong and durable immunity. The efficacy of Sputnik V for infection with the delta mutant is 83% and 94% for hospitalization. To date, Sputnik V has been registered in 70 countries in different parts of the world with a total population of over 4 billion.
RDIF’s role in initiating partnerships with other COVID vaccine producers
As part of a global effort to join forces in the fight against the pandemic, RDIF has begun partnerships with other vaccine producers to conduct joint mix-and-match research. The world’s first partnership of this kind was signed with AstraZeneca in December 2020 with the aim of conducting joint clinical trials of the combination of the AstraZeneca vaccine and the first component of Sputnik V (one-shot Sputnik light vaccine). I did. To date, joint clinical trials of Sputnik Light and AstraZeneca have been successfully underway in many countries (Argentina, Azerbaijan, Russia, United Arab Emirates), demonstrating the high safety and immunogenicity profile of this combination. I am.
The first component of Sputnik V (Sputnik Light) as a universal booster for other COVID vaccines
One Shot Sputnik Light is a highly effective vaccine both when used standalone and when applied as a booster. Sputnik Light is licensed in more than 15 countries and the registration process is underway in 30 more countries.
The latest findings from the Gamalaya Center, based on data from 28,000 subjects in Moscow, show that the stand-alone Sputnik Light vaccine was taken from a delta variant of the coronavirus during the first three months after vaccination. It has been shown to be 70% effective against infection. The vaccine is 75% effective among subjects under the age of 60.
The efficacy of one-shot Sputnik Light as a booster for delta variants of other vaccines is close to the efficacy of Sputnik V vaccines for delta variants. More than 83% for infections and more than 94% for hospitalizations.
Sputnik Light showed superior efficacy compared to several two-shot vaccines, which showed a significant reduction in efficacy against delta mutants of less than 50% 5 months after injection. Sputnik Light alone is much more effective against severe illness and hospitalization.
Clinical trials of the AstraZeneca / Sputnik Light combination have shown higher levels of immunogenicity than the original AstraZeneca vaccine.
The RDIF and the Argentine Ministry of Health are co-sponsoring the first multi-vaccine combination trial in 2,800 subjects (560 in the city and state of Buenos Aires and in each of the five states of Cordoba, La Rioja and San Luis).
Interim results from an Argentine study of Sputnik Light combined with vaccines produced by AstraZeneca, China National Pharmaceutical, Moderna and Cancino from more than 1,000 volunteers show that Sputnik Light is an effective universal booster for these vaccines. Indicates that Each “vaccine cocktail” combination with Sputnik Light has a higher antibody titer 14 days after the second dose compared to the original homogeneous (same vaccine as the first and second doses) regimen of each vaccine. Provided.
Argentine data also show a high safety profile when Sputnik Light is used in combination with all other vaccines, with no serious adverse events occurring after vaccination in any combination. ..
Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), said: producer. Clinical trials of the first component of Sputnik V (one-shot Sputnik Light vaccine) in combination with other vaccines are underway successfully worldwide. Sputnik Light has shown strong safety and immunogenicity results in a collaborative study, which is a universal booster and the best for re-vaccination of previously vaccinated individuals. This is one of the solutions. “
The mix-and-match approach pioneered by Sputnik V enhances and prolongs the immune response: RDIF
Source link The mix-and-match approach pioneered by Sputnik V enhances and prolongs the immune response: RDIF